Another Genmab drug from Janssen receives breakthrough therapy designation

The US FDA has given breakthrough therapy status to the cancer drug teclistamab which is based on Genmab's Duobody platform.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Shortly after Janssen secured approval from the US Food and Drug Administration (FDA) for the Genmab-developed lung cancer drug Rybrevant, the pharmaceutical company has taken a crucial step with another drug from Genmab's Duobody platform.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading